 Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc NASDAQ: VINC to 4 from 11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse. 